Evidence map›Paper›PMID 35346348›Full record

ArticleTrials2022

Clinical- and cost-effectiveness of a technology-supported and solution-focused intervention (DIALOG+) in treatment of patients with chronic depression-study protocol for a multi-site, cluster randomised controlled trial [TACK].

Philip McNamee, Aleksandra Matanov, Lauren Jerome, Sally Kerry, Neil Walker, Yan Feng, Andrew Molodynski, Shonagh Scott, Latha Guruvaiah, Sue Collinson and 4 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Philip McNameeUnit for Social and Community Psychiatry, Newham Centre for Mental Health, Cherry Tree Way, London, S13 8SP, UK. philip.mcnamee@nhs.net.ORCID http://orcid.org/0000-0002-6913-5662
Aleksandra MatanovUnit for Social and Community Psychiatry, Newham Centre for Mental Health, Cherry Tree Way, London, S13 8SP, UK.
Lauren JeromeUnit for Social and Community Psychiatry, Newham Centre for Mental Health, Cherry Tree Way, London, S13 8SP, UK.
Sally KerryPragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Queen Mary University, London, Yvonne Carter Building, 58 Turner Street, London, E1 2AB, UK.
Neil WalkerPragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Queen Mary University, London, Yvonne Carter Building, 58 Turner Street, London, E1 2AB, UK.
Yan FengPragmatic Clinical Trials Unit, Centre for Evaluation and Methods, Queen Mary University, London, Yvonne Carter Building, 58 Turner Street, London, E1 2AB, UK.
Andrew MolodynskiOxford Health NHS Foundation Trust, Research & Development, Warneford Lane, Headington, Oxford, OX3 7JX, UK.
Shonagh ScottSheffield Health and Social Care NHS Foundation Trust, Research & Development, Fulwood House, Old Fulwood Road, Sheffield, S10 3TH, UK.
Latha GuruvaiahGloucestershire Health and Care NHS Foundation Trust, Research & Development, Fritchie Centre, Charlton Lane, Cheltenham, GL53 9DZ, UK.
Sue CollinsonHomerton University Hospital, Homerton Row, London, E9 6SR, UK.
Rose McCabeCentre for Mental Health Research, City University of London, Northampton Square, London, EC1V 0HB, UK.
John GeddesDepartment of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Headington, Oxford, OX3 7JX, UK.
Stefan PriebeUnit for Social and Community Psychiatry, Newham Centre for Mental Health, Cherry Tree Way, London, S13 8SP, UK.
Victoria BirdUnit for Social and Community Psychiatry, Newham Centre for Mental Health, Cherry Tree Way, London, S13 8SP, UK. v.j.bird@qmul.ac.uk.
Centre for Mental Health · GBQueen Mary University of London · GBCity, University of London · GBGloucestershire Health and Care NHS Foundation Trust · GBHomerton University Hospital · GBOxford Health NHS Foundation Trust · GBSheffield Health and Social Care NHS Foundation Trust · GBWarneford Hospital · GB

Funding

Programme Grants for Applied Research RP-PG-0615-200010
6 · The paper itself

Abstract

backgroundMany with an acute depressive disorder go on to develop chronic depression, despite ongoing care. There are few specifically designed interventions to treat chronic depression. DIALOG+, a technology-assisted intervention based on the principles of solution-focused therapy, may be beneficial. It has been shown to be effective as a treatment for patients with psychotic disorders, especially in regards to increasing quality of life. DIALOG+ was designed to be flexibly applied and not diagnosis-specific, aiming to structure communication and generate a personally-tailored care plan. This cluster randomised controlled trial (RCT) is part of a programme of research to adapt and test DIALOG+ for patients with chronic depression.

methodsPatients will be eligible for the trial, if they have exhibited symptoms of depression or non-psychotic low mood for at least 2 years, have regular contact with a clinician and have a low subjective quality of life and moderate depressive symptoms. Clinicians, who routinely see eligible patients, will be recruited from a number of sites across NHS England. Clusters will have between 1 and 6 patients per clinician and will be randomised in a 1:1 ratio to either the intervention (DIALOG+) or active control group (treatment as usual + DIALOG scale). Clinicians in the intervention group are trained and asked to deliver the intervention regularly for 12 months. Active control participants receive treatment as usual and are asked to rate their satisfaction with areas of life and treatment on the DIALOG scale at the end of the clinical session. Approximately 112 clinician clusters will be recruited to reach a total patient sample size of 376. Clinical and social outcomes including costs are assessed at baseline and 3, 6 and 12 months post randomisation. The primary outcome will be subjective quality of life at 12 months. DISCUSSION: This definitive multi-site, cluster RCT aims to evaluate the clinical- and cost-effectiveness of DIALOG+ for people with chronic depression. If shown to be effective for this patient population it could be used to improve outcomes of mental health care on a larger scale, ensuring that patients with complex and co-morbid diagnoses can benefit.

trial registrationISRCTN11301686 . Registered on 13 Jun 2019.

Indexed as

DepressionPsychotic DisordersCost-Benefit AnalysisHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicTechnologyCluster randomised trialCommunity careDepressionMental healthSolution focused

Identifiers

PMID35346348
PMCPMC8960207
OpenAlexW4226185397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.